Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Milia-Like Papules and Ulcerated Nodules in a Man With Bartter Syndrome.

Actas dermo-sifiliograficas·2025
Same author

Generalized Pustular Psoriasis: Review and Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology.

Actas dermo-sifiliograficas·2025
Same author

Psychotropic Drugs: A Practical Guide for Use in Dermatology.

Actas dermo-sifiliograficas·2025
Same author

[Translated article] Methotrexate-Induced Gouty Arthritis in Psoriatic Patient.

Actas dermo-sifiliograficas·2025
Same author

Methotrexate-Induced Gouty Arthritis in Psoriatic Patient.

Actas dermo-sifiliograficas·2025
Same author

[Translated article] Updated Perspective from the Spanish Psoriasis Working Group (GPS) on Biosimilar Drug Use in Moderate-to-Severe Psoriasis.

Actas dermo-sifiliograficas·2025
Same journal

Fingolimod-associated lymphomatoid papulosis.

Actas dermo-sifiliograficas·2026
Same journal

Demodicosis: update and treatment with laser and other light sources.

Actas dermo-sifiliograficas·2026
Same journal

New treatments for adult female acne.

Actas dermo-sifiliograficas·2026
Same journal

First regulations of the Spanish Society of Dermatology (1909).

Actas dermo-sifiliograficas·2026
Same journal

Long-hair FUE: advantages and disadvantages of the most recent technique in hair transplantation.

Actas dermo-sifiliograficas·2026
Same journal

Sunburns, Tanning, and Social Media: A Descriptive Study Among Spanish University Students.

Actas dermo-sifiliograficas·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

[Infliximab: patients selection].

L Puig1

  • 1Servicio de Dermatología, Hospital de Santa Creu i Sant Pau, Barcelona, España. lpuig@santpau.es

Actas Dermo-Sifiliograficas
|December 17, 2008
PubMed
Summary
This summary is machine-generated.

Optimizing moderate/severe psoriasis treatment with infliximab (a TNF-blocking agent) requires careful patient selection, considering efficacy, safety, and long-term continuous therapy for best results.

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Related Experiment Videos

Last Updated: Jun 27, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Moderate to severe psoriasis necessitates optimized therapeutic strategies.
  • Infliximab is a biologic agent targeting TNF-alpha, used for psoriasis treatment.

Purpose of the Study:

  • To outline optimal patient selection and management strategies for infliximab therapy in moderate to severe psoriasis.
  • To emphasize the importance of individualized treatment plans, considering efficacy, safety, and long-term maintenance.

Main Methods:

  • Review of infliximab's efficacy, kinetics, and adverse effect profile in psoriasis.
  • Analysis of treatment response, including induction and maintenance phases.
  • Consideration of patient-specific factors like contraindications and psoriatic arthritis.

Main Results:

  • Rapid response to infliximab is typically observed by the second week.
  • Initial induction phase shows better response than repeated or intermittent treatment.
  • Fixed-schedule maintenance therapy is superior to on-demand treatment for psoriasis.

Conclusions:

  • Infliximab therapy should be planned as long-term continuous treatment for sustained efficacy and patient agreement.
  • Ideal candidates are patients with severe psoriasis requiring continuous systemic treatment and experiencing rapid relapses.
  • Careful consideration of contraindications and potential adverse effects is crucial, especially in patients with increased risk factors or psoriatic arthritis.